RxDoctor Payments Data

Emily Bowers

Rheumatology · Cincinnati, OHNPI 1609294727

Payments from drug & device makers

$10,243in general payments, 2019–2025

Across 728 payments — averaging $14.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • UCB, Inc.$2K
  • Amgen$713
  • AstraZeneca$702
  • Lilly USA, LLC$608
  • Novartis$426
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$10,238100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie330$4,704
UCB, Inc.198$1,697
Amgen(2 entities)48$713
AstraZeneca(2 entities)31$702
Lilly USA, LLC33$608
Novartis26$426
Johnson & Johnson16$342
Pfizer13$243
E.r. Squibb & Sons, L.L.C.12$196
Abbott2$163
GSK8$139
Janssen Scientific Affairs, LLC1$109
Organon3$64
Mallinckrodt Hospital Products Inc.3$57
Genentech USA, Inc.1$26
Mylan Institutional Inc.1$23
Radius Health, Inc.1$18
Boehringer Ingelheim1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,243 in reported general payments places this provider in the 75th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$68,208
Medicare patients
206
Services billed
1,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab64$433,263
Enbrel SureclickEtanercept43$354,840
RinvoqUpadacitinib55$349,396
Taltz AutoinjectorIxekizumab13$80,997
Orencia ClickjectAbatacept14$78,719
Cimzia (2 Pack)Certolizumab Pegol11$61,903
MethotrexateMethotrexate Sodium307$9,218
Hydroxychloroquine Sulfate248$9,099
OtrexupMethotrexate/Pf12$8,578
Leflunomide40$3,453
Colchicine42$2,963
Pregabalin72$2,145
Prednisone393$1,938
Mycophenolate Mofetil23$1,505
Celecoxib55$1,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$4,704$349,39655 claims
UCB, Inc.Cimzia (2 Pack)$1,697$61,90311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →